Elevance raises 2026 adjusted EPS guidance to at least $29, targets 12% growth in 2027
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: Elevance Health (ELV) Q3 2026 MANAGEMENT VIEW * "Elevance Health delivered strong third quarter results with Medicaid, Medicare Advantage and Individual ACA, each contributing to our better-than-expected performance," said President, CEO & Director Gail…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA guidance raise from a major managed care company can move the sector and the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Elevance revises its 2026 adjusted diluted EPS guidance to at least $29.
- 02The 2026 earnings baseline rises to at least $26.75.
- 03The company remains confident in at least 12% adjusted diluted EPS growth in 2027.
- 04The Elevate platform has identified more than $300 million in anticipated savings this year.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets